Autoimmune: Page 2

Prometheus Biosciences announces $500M stock offering

By LabPulse.com staff writers

The San Diego-based biotech company is taking a precision medicine approach for the discovery, development, and commercialization of therapeutic and companion diagnostic products for the treatment of immune-mediated diseases.

December 12, 2022

CRISPR may enable rapid, sensitive test for COVID-19

By Joseph Constance

The device has the potential for use as a diagnostic test at the point of care (POC), according to its developers.

September 26, 2022

DxTerity receives NY authorization for SLE test

By LabPulse.com staff writers

The DxTerity test is designed for patients with systemic lupus erythema (SLE), which affects up to one million patients in the U.S.

September 15, 2022

Aptorum provides update on its rapid MDx technology

By LabPulse.com staff writers

The technology has been clinically validated in more than 100 patient samples, Aptorum said.

September 14, 2022

Prometheus, Takeda launch prognostic tool for Crohn’s

By LabPulse.com staff writers

According to Prometheus, CDPath is a personalized risk assessment tool that can be used in combination with a physician's clinical assessment to evaluate an adult patient's risk for developing serious complications of CD such as bowel strictures, internal penetrating disease, or non-perianal surgery within three years.

September 14, 2022

Nordic touts PRO-C6 biomarker for heart failure clinical trials

By LabPulse.com staff writers

In collaboration with Bristol Myers Squibb and the University of Pennsylvania, researchers combined analyses of six independent cohorts of HFpEF patients from around the globe, which are being evaluated with the PRO-C6 biomarker.

September 13, 2022

N-antigen levels point to COVID severity in NIH study

By Jared Berberabe

The study by researchers at the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) was a cross-sectional follow-up analysis involving 2,540 participants who had been previously enrolled in the Therapeutics for Inpatients with COVID-19 (TICO) platform trial.

September 8, 2022

Lunaphore, Nucleai to provide AI-based spatial biology analysis

By LabPulse.com staff writers

Combining Lunaphore's Comet hyperplex staining and imaging platform, a fully automated sequential immunofluorescence (seqIF) instrument, with Nucleai's Atom artificial-intelligence (AI) spatial biology platform will enable the companies to generate new insights from tissue biopsies and provide labs with an integrated end-to-end spatial biology workflow.

September 8, 2022

Week in Review: At-home flu testing, asymptomatic monkeypox, telediagnostic accuracy, and more

By Leo O'Connor

Dear LabPulse.com member,

September 7, 2022

IsoPlexis joins MediMergent, CCBD for COVID-19 study

By LabPulse.com staff writers

The large multisite study will focus on the functionality of immune cells and their role in prevention of breakthrough COVID-19 infections in immunocompromised patients following administration of AstraZeneca's AZD7442 IM or IV antibody combination.

September 5, 2022

NfL IDs patients predisposed to neurotoxic complications

By LabPulse.com staff writers

Analyzing blood samples from patients before, during, and after CAR-T cell therapy, Washington University School of Medicine researchers found that levels of neurofilament light chain (NfL) proteins are higher in patients who develop neurotoxic complications.

August 31, 2022

Week in Review: Room-temperature CRISPR, Roche T-cell test for COVID response, Qiagen monkeypox syndromic panel, and more

By Leo O'Connor

Dear LabPulse.com member,

August 17, 2022

Previous Page

Page 2 of 10

Next Page